Effects of Mobile Health Technology Interventions on Body Weight and Liver Enzymes in Patients With Nonalcoholic Fatty Liver Disease

Objective: To systematically evaluate the effects of mobile health (mHealth) technology interventions on body weight and liver enzyme levels in patients with nonalcoholic fatty liver disease (NAFLD). Methods: Randomized controlled trials (RCTs) investigating mHealth interventions for NAFLD patients were retrieved from CNKI, Wanfang, VIP, CBM, PubMed, Cochrane Library, Embase, and Web of Science databases from inception to March 2025. Data analysis was conducted using RevMan 5.2 software. Results: Ten RCTs involving 1489 patients were included. The meta-analysis demonstrated that mHealth interventions significantly reduced body weight [standardized mean difference (SMD)=−1.93, 95% CI (−3.08, −0.77)], aspartate aminotransferase (AST) [SMD=−1.27, 95% CI (−2.01, −0.54)], and alanine transaminase (ALT) [SMD=−1.48, 95% CI (−2.20, −0.76)] compared with control groups (all P <0.05). Conclusion: This meta-analysis demonstrates that mHealth technology interventions are effective for weight loss and improvement of liver enzymes in patients with NAFLD, positioning them as a promising and scalable long-term management strategy.